Power Law company profile

Kiniksa Pharmaceuticals

Biotech & Life Sciences · Lexington, United States · Founded 2015 · IPO 2018 Unicorn

Kiniksa Pharmaceuticals is developing therapies for inflammatory and autoimmune conditions

Valuation

$3.68B

Market cap · May/2026

Revenue

$678M

Latest reported FY

EBITDA

$177M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where Kiniksa Pharmaceuticals has talent and traffic

Workforce by country

5 countries with
team presence

🇺🇸 United States94.5%

🇬🇧 United Kingdom2.1%

🇨🇭 Switzerland2.1%

🇳🇱 Netherlands0.4%

🇮🇳 India0.4%

5 countries shown

Web traffic by country

17K monthly visits
across markets

🇺🇸 United States89.4%

🇮🇳 India8.2%

Top 2 markets shown

Market sentiment

What the market is saying about Kiniksa Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Kiniksa Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kiniksa Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles